

Donor and recipient sex in allogeneic stem cell transplantation: what really matters

Haesook T. Kim,¹ Mei-Jie Zhang,² Ann E. Woolfrey,³ Andrew St. Martin,⁴ Junfang Chen,⁴ Wael Saber,⁴ Miguel-Angel Perales,⁵ Philippe Armand⁶ and Mary Eapen⁴

¹Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA; ²Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI; ³Department of Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA; ⁴Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; ⁵Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY; and ⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2016.147645

Received: April 9, 2016.

Accepted: June 23, 2016.

Pre-published: June 27, 2016.

Correspondence: htkimc@jimmy.harvard.edu

Table S1. Outcome by recipient sex and recipient and donor sex combination

Patient Sex	N	4y OS (95CI)	4y PFS (95CI)	4y CIR (95CI)	4y NRM (95CI)
Female	4960	45% (43-46)	36% (35-37)	41% (40-42)	23% (22-24)
Male	6837	41% (40-42)	33% (31-34)	43% (42-44)	24% (23-25)
p-value		0.001	0.0005	0.018	0.07
Donor & Patient Sex	N	4y OS (95CI)	4y PFS (95CI)	4y CIR (95CI)	4y NRM (95CI)
M→F	2899	45% (43-47)	37% (35-38)	40% (38-42)	23% (22-25)
F → F	2061	44% (42-46)	35% (33-37)	42% (40-44)	23% (21-24)
M → M	4349	41% (40-43)	33% (31-34)	44% (42-45)	23% (22-24)
F → M	2488	40% (38-42)	32% (30-34)	42% (40-44)	26% (24-28)
p-value		0.01 ^a	0.006 ^b	0.03 ^c	0.045 ^d

OS: overall survival; PFS: progression-free survival; CIR: cumulative incidence of relapse; NRM: cumulative incidence of non-relapse mortality. For OS and PFS, stratified log-rank test was used. For CIR and NRM, Gray test was used.

a: for comparison of all 4 cohorts. P=0.88 for M->F vs. F->F; P=0.60 for M->M vs. F->M

b: for comparison of all 4 cohorts. P=0.59 for M->F vs. F->F; P=0.96 for M->M vs. F->M

c: for comparison of all 4 cohorts. P=0.009 for the comparison between M->M and other 3 cohorts combined.

d: for comparison of all 4 cohorts. P=0.0075 for the comparison between F->M and other 3 cohorts combined

Table S2. Chronic GVHD outcome by graft source

Donor & Patient Sex	PB			BM		
	N	1y Cum Inc (95% CI)	p-value	N	1y Cum Inc (95% CI)	p-value
M→F	2376	39% (37-41)	ref	404	22% (18-26)	ref
F → F	1698	40% (38-42)	0.3	281	27% (22-32)	0.2
M → M	3641	37% (36-39)	0.17	548	29% (25-33)	0.013
F → M	2107	42% (40-44)	0.011	275	37% (32-43)	0.0001

1 year cumulative incidence of cGVHD in PB was 40% vs 39% for male and female recipients ($p=0.67$); 1 year cumulative incidence of cGVHD in BM was 24% vs 32% for male and female recipients ($p=0.0012$).